DOCSLIB.ORG

1. X-R, O N 1999;63:1-38

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1. X-R, O N 1999;63:1-38 USOO6423719B1 (12) United States Patent (10) Patent No.: US 6,423,719 B1 Lawyer (45) Date of Patent: Jul. 23, 2002 (54) METHOD FOR TREATING BENIGN Hasan et al., “Antagonism of coronary artery relaxation by PROSTATE HYPERPLASA adenosine AA-receptor antagonist ZM241385,” J Cardio vasc Pharmacol. 2000 Feb.; 35(2):322–5. (75) Inventor: Carl H. Lawyer, Mequon, WI (US) Kotera et al., “Immunohistochemical localization of c(GMP binding c(GMP-specific phosphodiesterase (PDE5) in rat (73) Assignee: Upsher-Smith Laboratories, Inc., tissues,” J Histochem Cytochem. 2000 May;48(5):685–93. Minneapolis, MN (US) Landells et al., “The role of adenosine receptors in the action of theophylline on human peripheral blood mononuclear (*) Notice: Subject to any disclaimer, the term of this cells from healthy and asthmatic Subjects.” BrJ Pharmacol, patent is extended or adjusted under 35 2000 Mar.; 129(6):1140–4. U.S.C. 154(b) by 0 days. Lew et al., “Examination of adenosine receptor-mediated relaxation of the pig coronary artery,” Clin Exp Pharmacol (21) Appl. No.: 09/505,220 Physiol, 1999 May–Jun.; 26(5–6):438–43.* Li et al., “Adenosine A receptors increase arterial endot (22) Filed: Feb. 16, 2000 helial cell nitric oxide,” J Surg Res, 1998 Dec.; Related U.S. Application Data 80(2):357-64.* (60) Provisional application No. 60/120,099, filed on Feb. 16, Li et al., “Adenosine enhances nitric oxide production by 1999. vascular endothelial cells,” Am J Physiol, 1995 Aug.; 269(2 Pt 1):C519-23.* (51) Int. Cl. ................................................ A61K 31/52 Olanrewaju et al., “Adenosine A and A receptors in cultured human and porcine coronary artery endothelial (52) U.S. Cl. ............................. 514/263; 514/8; 514/12; cells,” Am J Physiol Heart Circ Physiol, 2000 Aug.; 279(2):H650–6.* 514/15; 514/264; 514/265; 514/922 Rump et al., “Adenosine mediates nitric-oxide-independent renal vasodilation by activation of AA receptors,” J Hyper (58) Field of Search ................................ 514/8, 12, 15, tens. 1999 Dec.; 17(12 Pt. 2):1987–93.* 514/263,264, 265,922 Schmeichel et al., “Methylxanthine bronchodilators poten (56) References Cited tiate multiple human neutrophil functions,” J Immunol. 1987 Mar; 138(6):1896–903.* U.S. PATENT DOCUMENTS Schmidt et al. “The Effect of Selective and Non-selective 2,575,344 A 11/1951 Jones et al. Phosphodiesterase Inhibitors on Allergen- and Leukotriene 4,031,218 A 6/1977 El-Antably C(4)-Induced Contractions in Passively Sensitized Human 4,187,308 A 2/1980 Franzone et al. Airways.” Br J Pharmacol. 2000 Dec.;131(8): 1607–18.* 4,341,783 A 7/1982 Scheindlin ShneyvayS et al., “Induction of apoptosis in cardiac myo 4,581,359 A 4/1986 Ayres cytes by an A. adenosine receptor agonist, Exp Cell ReS. 5,171,217 A 12/1992 March et al. ................. 604/53 1998 Sep.; 243(2):383-97.* 5,753,641 A 5/1998 Gormley et al. ShneyvayS et al., “Induction of apoptosis in rat cardiocytes 5,891,904. A 4/1999 Stief et al. by A. adenosine receptor activation and its Suppression by OTHER PUBLICATIONS isoproterenol.” Exp Cell Res. 2000 May; 257(1):111-26.* Chemical Abstracts 121:50051, “Ocular hypotension (List continued on next page.) induced by topical dopaminergic drugs and phosdiesterase inhibitors” (1994).* Primary Examiner Frederick Krass Kukovetz et al., “Overadditive Synergism Between Theo (74) Attorney, Agent, or Firm- Mueting, Raasch & phylline, Diprophylline and Proxyphylline in Tracheal Gebhardt, PA. Smooth Muscle Relaxation, Arzneimittelforschung, (57) ABSTRACT 33(10): 1450–1454 (1983). Brambilla et al., “Activation of the A. adenosine receptor A method of treating and/or preventing renal dysfunction in affects cell cycle progression and cell growth,” Naunyn a patient, Such as renal colic or contrast nephropathy by Schmiedeberg's Arch Pharmacol, 2OOO Mar.; administering to a patient, a compound of the formula: 361(3):225–34. Brodie et al., “Activation of the AA adenosine receptor O i inhibits nitric oxide production in glial cells,” FEBS Lett. R1 1998 Jun.; 429(1):139–42. NN N Conti et al., “The Molecular Biology of Cyclic Nucleotide Phosphodiesterases,” Prog Nucleic Acid Res Mol Biol. 1. X-R, O N 1999;63:1-38. Conti, "Phosphodiesterases and cyclic nucleotide Signaling R2 in endocrine cells,” Mol Endocrinol. 2OOO Sep.;14(9): 1317-27. Granovsky et al., “Identification of the gamma Subunit-int is described herein. Administration of dyphylline in a Sus eracting residues on photoreceptor cGMP phosphodi tained release oral dosage form is preferred. esterase, PDE6.O., J Biol Chem. 2000 Dec. 29:275(52):41258–62. 21 Claims, No Drawings US 6,423,719 B1 Page 2 OTHER PUBLICATIONS Acara et al., “Probenecid inhibition of the renal excretion of This Week in Science: from Science. Jun. 9, 2000; dyphylline in chicken, rat and man,” J. Pharm. Pharmacol., 288(5472): 1701.* 39(7):526-530 (1987). Walker et al., “Adenosine A receptor activation delayS Becker et al., “The effect of the specific phosphodi apoptosis in human neutrophils,” J Immunol, 1997 Mar.; esterase-IV-inhibitor rollipram on the ureteral peristalsis of 158(6):2926–31.* the rabbit in vitro and in vivo,” J. Urol., 160(3Pt. 1): 920–925 Xu et al., “Atomic Structure of PDE4: Insights into Phos (1998). phodiesterase Mechanism and Specificity,” Science. Jun. 9, Drescher et al., “Alpha-1 receptor mediated Smooth muscle 2000; 288:822-1825.* regulation in benign prostatic hyperplasia,” Scand. J. Urol. Yasui et al., “Effects of theophylline on human eosinophil Nephrol. Suppl., 157:33–40 (1994). functions: comparative Study with neutrophil functions,” J Drescher et al., “Smooth Muscle Contractility in Prostatic Leukoc Biol. 2000 Aug.; 68(2):194–200.* Hyperplasia: Role of Cyclic Adenosine Monophosphate,” Yasui et al., “Theophylline induces neutrophil apoptosis Prostate, 25(2):76–80 (1994). through adenosine A receptor antagonism,” J. Leukoc Biol. 2000 Apr.; 67(4):529–35.* Drescher et al., letter to Editor (regarding “Nephrotoxicity Andersson, “The Concept of Uroselectivity,” Eur: Urol., from contrast media: attenuation with theophylline,” which 33(Suppl. 2):7-11 (1998). appeared in Radiology, 195(1):17-22 (1995)), Radiology, Bang et al., “Cyclic AMP induces transforming growth 197(2):547-548 (1995). factor B2 gene expression and growth arrest in the human Drescher, “Ca" and Cyclic Adenosine Monophosphate androgen-independent prostate carcinoma cell line PC-3.” Involvement in Radiographic Contrast Medium-induced Proc. Natl. Acad. Sci. USA, 89(8):3556-3560 (1992). Renal Vasoconstriction.” J. Vasc. Interv. Radiol, Barza, “Anatomical Barriers for Antimicrobial Agents,” Eur: 6(5):813–818 (1995). J. Clin. Microbiol. Infect. Dis., 12(Suppl. 1):S31-S35 Erley et al., “Adenosine antagonist theophylline prevents the (1993). reduction of glomerular filtration rate after contrast media Boatman et al., “Pharmacological Evaluation of Ureteral application,” Kidney Int., 45(5):1425-1431 (1994). Smooth Muscle, A Technique for Monitoring Ureteral Peri Gladstone et al., “The use of theophylline ethylene diamine stalsis.” Invest. Urol, 4(6):509-520 (1967). (aminophylline) for the relief of biliary collic: a preliminary Coe et al., “The Pathogenesis and Treatment of Kidney report,” J. Am. Med. Assoc., 126(17): 1084-1085 (1944). Stones,” N. Engl. J. Med., 327(16):1141-1152 (1992). Edelstein et al., “Chapter 8: Etiology, Pathogenesis, and Katholiet al., “Nephrotoxicity from Contrast Media: Attenu Management of Renal Failure.” Campbell's Urology, 7" ation with Theophylline,” Radiology, 195(1):17–22 (1995). edition, Walsh et al., eds., W.B. Saunders Co., Philadelphia, King et al., “Purinergic Modulation of Rat Urinary Bladder Title page, publication page, table of contents, and pp. Detrusor Smooth Muscle,” Gen. Pharmacol., 315–341 (1998). 29(4):597–604 (1997). Fair et al., “The pH of Prostatic Fluid: A Reappraisal and Kolonko et al., “The nonselective adenosine antagonist Therapeutic Implications,” J. Urol., 120(6):695-698 (1978). theophylline does prevent renal dysfunction induced by Fang et al., “P-Purinergic Receptor Agonists Inhibit the radiographic contrast agents,” J. Nephrology, 11(3):151-156 Growth of Androgen-independent Prostate Carcinoma (1998). Cells,” J. Clin. Invest., 89(1):191-196 (1992). Lawyer et al., “Utilization of intravenous dihydroxypropyl Kawabe et al., “Use of an O. 1-Blocker, YM617, in the theophylline (dyphylline) in an aminophylline-Sensitive Treatment of Benign Prostatic Hypertrophy,” J. Urol., patient, and its pharmacokinetic comparison with theophyl 144(4):908–912 (1990). Kerttula et al., “Theophylline infusion modulates prostag line,” J. Allergy Clin. Immunol., 65(5):353–357 (1980). landin and leukotriene production in man,” ProStaglandins May et al., “Effect of probenecid on dyphylline elimination,” Leukot. Essent. Fatty Acids, 57(6):555-560 (1997). Clin. Pharmacol Therapeut., 33(6):822–825 (1983). Leoniet al., “the Effects of Isoproterenol and Aminophylline Morcos et al., “Nephrotoxicity from Contrast Media: on Detrusor Muscle Contractility in an Organ Bath Appa Attenuation with Theophylline,” letter to Editor (regarding ratus.” Invest. Urol., 10(6):458–463 (1973). “Nephrotoxicity from contrast media: attenuation with theo Martin et al., “Relationship Between the Effects of Alfuzosin phylline,” which appeared in Radiology, 195(1):17-22 on Rat Urethral and Blood Pressures and its Tissue Con (1995)), Radiology, 197(2):546–547 (1995). centrations,” Life Sci., 63(3):169-176 (1998). Morcos et al., “Contrast Media-induced Nephrotoxicity: A Martin et al., “Functional Uroselectivity.” Eur: Urol., New Insight,” Clin. Radiol., 52(8):573–574 (1997). 33(Suppl. 2):12-18 (1998). Nadai et al., “Pharmacokinetics and the Effect of Probenecid Nolan, “Theophylline option for attenuating contrast medi on the Renal Excretion Mechanism of Diprophylline,” J. a-induced nephrotoxicity in patients on metformin, Am. J. Pharm. Sci., 81 (10): 1024–1027 (1992). Health-Syst. Pharm., 54(5):587–588 (1997). Oesterling, “Benign Prostatic Hyperplasia-Medical and OSSwald et al., “Therapeutic use of theophylline to antago Minimally Invasive Treatment Options,” N.
Load more

Recommended publications
  • Aminophylline Catalog Number A1755 Storage
    Aminophylline Catalog Number A1755 Storage Temperature –20 °C Replacement for Catalog Number 216895 CAS RN 317-34-0 Storage/Stability Synonyms: theophylline hemiethylenediamine complex; Aminophylline should be kept tightly closed to prevent 3,7-dihydro-1,3-demethyl-1H-purine-2,6-dione CO2 absorption from the atmosphere, which leads to compound with 1,2-ethanediamine (2:1); formation of theophylline and decreased solubility in 1,2 3 (theophylline)2 • ethylenediamine aqueous solutions. Stock solutions should be protected from light and prevented from contact with Product Description metals.2 Molecular Formula: C7H8N4O2 ·1/2 (C2H8N2) Molecular Weight: 210.3 References 1. The Merck Index, 12th ed., Entry# 485. Aminophylline is a xanthine derivative which is a 2. Martindale: The Extra Pharmacopoeia, 31st ed., combination of theophylline and ethylenediamine that is Reynolds, J. E. F., ed., Royal Pharmaceutical more water soluble than theophylline alone. Society (London, England: 1996), pp. 1651-1652. Aminophylline has been widely used as an inhibitor of 3. Data for Biochemical Research, 3rd ed., Dawson, cAMP phosphodiesterase.3 R. M. C., et al., Oxford University Press (New York, NY: 1986), pp. 316-317. Aminophylline has been shown to limit 4. Pelech, S. L., et al., cAMP analogues inhibit phosphatidylcholine biosynthesis in cultured rat phosphatidylcholine biosynthesis in cultured rat hepatocytes.4 It has been used in studies of acute hepatocytes. J. Biol. Chem., 256(16), 8283-8286 hypoxemia in newborn and older guinea pigs.5 The (1981). effect of various xanthine derivatives, including 5. Crisanti, K. C., and Fewell, J. E., Aminophylline aminophylline, on activation of the cystic fibrosis alters the core temperature response to acute transmembrane conductance regulator (CFTR) chloride hypoxemia in newborn and older guinea pigs.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Proxyphylline Item No. 20937 CAS Registry No.: 603-00-9 Formal Name: 3,7-dihydro-7-(2-hydroxypropyl)-1,3- N dimethyl-1H-purine-2,6-dione O N Synonym: NSC 163343 C H N O MF: 10 14 4 3 N FW: 238.2 N Purity: ≥98% O UV/Vis.: λmax: 273, 324 nm Supplied as: A crystalline solid OH Storage: -20°C Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly Laboratory Procedures Proxyphylline is supplied as a crystalline solid. A stock solution may be made by dissolving the proxyphylline in the solvent of choice. Proxyphylline is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of proxyphylline in ethanol is approximately 1 mg/ml and approximately 10 mg/ml in DMSO and DMF. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of proxyphylline can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of proxyphylline in PBS, pH 7.2, is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description Proxyphylline is a methylxanthine derivative that has bronchodilatory actions.1 It has also been reported 2 to have vasodilatory and cardiac stimulatory effects.
    [Show full text]
  • The Latin Language and Medical Terminology
    T. Titiyevska, O. Gordiyenko, A. Kulichenko THE LATIN LANGUAGE AND MEDICAL TERMINOLOGY QUIZZES AND TASKS FOR PRACTICAL SKILLS EVALUATION for the First-Year Students of the Medical Faculties with the English Medium of Instruction, Specialty 222 “General Medicine” Zaporizhzhia 2019 1 Zaporizhzhia State Medical University Department of Foreign Languages T. Titiyevska, O. Gordiyenko, A. Kulichenko THE LATIN LANGUAGE AND MEDICAL TERMINOLOGY QUIZZES AND TASKS FOR PRACTICAL SKILLS EVALUATION for the First-Year Students of the Medical Faculties with the English Medium of Instruction, Specialty 222 “General Medicine” Zaporizhzhia 2019 2 UDC 811.124:[001.4:61](076.1) T64 A manual is approved and recommended for using in learning process by the Central Methodical Commission of Zaporizhzhia State Medical University (record No. 1 from September 26, 2019). Reviewers: S. Chugin, PhD (Medicine), Associate Professor, Department of Human Anatomy, Operative Surgery and Topographic Anatomy, Zaporizhzhia State Medical University. R. Shramko, PhD (Philology), Associate Professor, Department of English and German Philology, Poltava V.G. Korolenko National Pedagogical University. Authors: T. Titiyevska, Senior Lecturer, Department of Foreign Languages, Zaporizhzhia State Medical University. O. Gordiyenko, PhD (Philology), Associate Professor, Department of Foreign Languages, Zaporizhzhia State Medical University. A. Kulichenko, PhD (Pedagogics), Associate Professor, Department of Foreign Languages, Zaporizhzhia State Medical University. Е The Latin Language and Medical Terminology. Quizzes and Tasks for Practical Skills Evaluation for the First-Year Students of the Medical Faculties with the English Medium of Instruction, specialty 222 “General Medicine” = Латинська T64 мова та медична термінологія. Зб. завд. для самост. роб. та завд. для перев. практ. навич. у студ.-іноз.
    [Show full text]
  • Comparing Retention in Xanthines Separation Between a Silica and Titania Stationary Phase in HPLC
    22 General Comparing retention in xanthines separation between a silica and titania stationary phase in HPLC Agnieszka PIWIEN Introduction The Objective of analytical chemistry is to determine chemical composi- Fig.1. Dependence of retention factor Lnk to % tions. of ACN in mobile phase in Aquasil column, Nowadays, it mostly relies on instrumental methods. Research conditions: !ow rate 200μL/min, ACN-Water (v/v) focuses on discovering new materials and chromatography principles. Columns with a silica layer are currently being used as a stationary phase in high performance liquid chromatography (HPLC). Owing to their low mechanical, thermal and pH stability the scientists are forced to investi- gate the different column supports. Therefore, the study on titanium support column was performed on the grounds of its strong Lewis acid sites probably resistant to changes of pH. The aim of these experiments was to compare the effectiveness of these two columns. Experimental methods First of all the xanthines and their derivatives were analyzed in the silica column Aquasil (50mm x 2,1mm I.D., 1,9m) in RPLC mode then in the Fig.2. Dependence of retention factor Lnk to % titanium dioxide column SachtoporeNP (100mm x 2,1mm I.D., 5m) in of water in mobile phase in Sachtopore column, HILIC mode. The Titania column was also studied under the influence of a conditions: !ow rate 200μL/min, ACN-Water mobile phase with and without a buffer solution. (v/v) All solutions were prepared using deionized water (Elga LAB WATER) and acetonitrile in a 1:1 (v/v) ratio. Uracile and naphthalene were respectively used as dead time markers, the former in the RP mode and the latter in HILIC mode (Hydrophilic interaction liquid chromatography).
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0304998 A1 Sem (43) Pub
    US 20100304998A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0304998 A1 Sem (43) Pub. Date: Dec. 2, 2010 (54) CHEMICAL PROTEOMIC ASSAY FOR Related U.S. Application Data OPTIMIZING DRUG BINDING TO TARGET (60) Provisional application No. 61/217,585, filed on Jun. PROTEINS 2, 2009. (75) Inventor: Daniel S. Sem, New Berlin, WI Publication Classification (US) (51) Int. C. GOIN 33/545 (2006.01) Correspondence Address: GOIN 27/26 (2006.01) ANDRUS, SCEALES, STARKE & SAWALL, LLP C40B 30/04 (2006.01) 100 EAST WISCONSINAVENUE, SUITE 1100 (52) U.S. Cl. ............... 506/9: 436/531; 204/456; 435/7.1 MILWAUKEE, WI 53202 (US) (57) ABSTRACT (73) Assignee: MARQUETTE UNIVERSITY, Disclosed herein are methods related to drug development. Milwaukee, WI (US) The methods typically include steps whereby an existing drug is modified to obtain a derivative form or whereby an analog (21) Appl. No.: 12/792,398 of an existing drug is identified in order to obtain a new therapeutic agent that preferably has a higher efficacy and (22) Filed: Jun. 2, 2010 fewer side effects than the existing drug. Patent Application Publication Dec. 2, 2010 Sheet 1 of 22 US 2010/0304998 A1 augavpop, Patent Application Publication Dec. 2, 2010 Sheet 2 of 22 US 2010/0304998 A1 g Patent Application Publication Dec. 2, 2010 Sheet 3 of 22 US 2010/0304998 A1 Patent Application Publication Dec. 2, 2010 Sheet 4 of 22 US 2010/0304998 A1 tg & Patent Application Publication Dec. 2, 2010 Sheet 5 of 22 US 2010/0304998 A1 Patent Application Publication Dec.
    [Show full text]
  • Enabling Direct Preferential Crystallization in a Stable Racemic
    Enabling Direct Preferential Crystallization in a Stable Racemic Compound System Lina Harfouche, Clément Brandel, Yohann Cartigny, Joop ter Horst, Gérard Coquerel, Samuel Petit To cite this version: Lina Harfouche, Clément Brandel, Yohann Cartigny, Joop ter Horst, Gérard Coquerel, et al.. Enabling Direct Preferential Crystallization in a Stable Racemic Compound System. Molecular Pharmaceutics, American Chemical Society, 2019, 16 (11), pp.4670-4676. 10.1021/acs.molpharmaceut.9b00805. hal- 02331962 HAL Id: hal-02331962 https://hal-normandie-univ.archives-ouvertes.fr/hal-02331962 Submitted on 24 Oct 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Enabling Direct Preferential Crystallization in a Stable Racemic Compound System Lina C. Harfouche,† Clément Brandel,†* Yohann Cartigny,† Joop H. ter Horst,‡ Gérard Coquerel,† and Samuel Petit† † Universite de Rouen Normandie, UFR des Sciences et Techniques, Laboratoire SMS-EA3233, Place Emile Blondel, 76821, Mont-Saint-Aignan, France ‡EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation (CMAC), Strathclyde Insti- tute of Pharmacy and Biomedical Sciences (SIPBS), Technology and Innovation Centre, University of Strathclyde, 99 George Street, Glasgow G1 1RD (UK) Supporting Information Placeholder 8 ABSTRACT: The preparative resolution by preferential crystal- separation methods, including chiral chromatography and enzy- 9 lization (PC) of proxyphylline has been achieved despite the matic resolution.
    [Show full text]
  • Asthma (1 of 26)
    Asthma (1 of 26) 1 Patient presents w/ signs & symptoms suggestive of asthma 2 3 DIAGNOSIS No ALTERNATIVE Is asthma DIAGNOSIS confi rmed? Yes ASSESS THE LEVEL OF CONTROL OF ASTHMA FOR THE PAST 4 WEEKS Controlled Partly Controlled Uncontrolled (All of the (Presence of 1-2 of these) (Presence of 3-4 of these) following) Children Adolescents Children Adolescents & ≤5 years old & Children ≤5 years old Children 6-11 years old 6-11 years old Frequency of daytime None >Few >2x/week >Few >2x/week symptoms minutes, minutes, >once a week >once a week Limitation of activities None Any Any Any Any Nocturnal waking up or None Any Any Any Any coughing due to asthma Need for reliever None >once/week >2x/week >once/week >2x/week medication* *Reliever medications taken prior to exercise excluded. Modified from: Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: Updated 2020. TREATMENT A Patient/guardian/caregiver education B Initial treatment of asthma C Management plans for long-term asthma control D Primary prevention E © Periodic assessmentMIMS & monitoring Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B13 © MIMS Pediatrics 2020 Asthma (2 of 26) 1 ASTHMA • A heterogeneous disease w/ chronic infl ammatory disorder of the airways • e most common chronic disease in pediatric age groups that causes signifi cant morbidity • Characterized by history of respiratory symptoms eg wheeze, shortness of breath, chest tightness & cough
    [Show full text]
  • 1120 Bronchodilators and Anti-Asthma Drugs
    1120 Bronchodilators and Anti-asthma Drugs Profile Preparations unchanged in the urine with an elimination half-life of about 2 Cilomilast is a phosphodiesterase type-4 inhibitor that has been Proprietary Preparations (details are given in Part 3) hours. Diprophylline is distributed into breast milk. investigated in the treatment of chronic obstructive pulmonary Arg.: Bronq-C; Clembumar; Oxibron; Austria: Spiropent; Chile: Airum; disease. Uses and Administration Asmeren; Broncotosil†; Cz.: Spiropent; Ger.: Contraspasmin†; Spiropent; Diprophylline is a theophylline derivative which is used similar- Gr.: Spiropent; Hong Kong: Clenasma†; Hung.: Spiropent; Indon.: Spiropent; Ital.: Clenasma†; Monores; Prontovent†; Spiropent; Jpn: ly to theophylline (p.1146) as a bronchodilator in reversible air- Spiropent; Mex.: Novegam; Oxyflux; Spiropent; Philipp.: Spiropent; ways obstruction. Clenbuterol Hydrochloride (BANM, rINNM) ⊗ Port.: Broncoterol; Cesbron; Spain: Spiropent†; Ventolase; Venez.: Brodi- The usual oral dose of diprophylline is up to 15 mg/kg every 6 lan; Brodilin; Buclen; Clenbunal; Risopent. Clenbutérol, chlorhydrate de; Clenbuteroli hydrochloridum; Hid- hours. It has also been given intramuscularly. Diprophylline is Multi-ingredient: Arg.: Mucosolvon Compositum; Oxibron NF; Aus- rocloruro de clenbuterol; Klenbuterol hydrochlorid; Klenbuterol- also an ingredient of preparations that have been promoted for tria: Mucospas; Ger.: Spasmo-Mucosolvan; Mex.: Ambodil-C; Balsibron- coughs. hidroklorid; Klenbuterolhydroklorid; Klenbuterolihydrokloridi;
    [Show full text]
  • Video Course Evaluation Form My Name Is
    Garden State CLE 2000 Hamilton Avenue Hamilton, New Jersey 08619 (609) 584-1924 – Phone (609) 584-1920 - Fax Video Course Evaluation Form My Name is: __________________________________________ Name of Course: ______________________________________ My Street address: _____________________________________ City: _____________________ State: _____ Zip Code: ____ Email Address: ________________________________________ Please Circle the Appropriate Answer Instructors: Poor Satisfactory Good Excellent Materials: Poor Satisfactory Good Excellent CLE Rating: Poor Satisfactory Good Excellent Required: Secret words that appeared on the screen during the seminar. 1) __________________________ 2) _______________________ 3) __________________________ 4) _______________________ What did you like most about the seminar? _____________________________________________________________ _____________________________________________________________ What criticisms, if any, do you have? _____________________________________________________________ _____________________________________________________________ I certify that I watched, in its entirety, the above-listed CLE Course. Signature ___________________________________ Date_________ In order to receive your CLE credits, please send our payment and this completed form to Garden State CLE, 2000 Hamilton Avenue, Hamilton, New Jersey, 08619. BURLINGTON COUNTY BAR ASSOCIATION --- Interpreting Your Client’s Drug Lab Results: Were They Impaired? © Chris Baxter 2020 DO LAB RESULTS MATTER IN A DUI-D? YES ➢State
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]